Richard T Owen

Summary

Affiliation: Thomson Reuters
Country: UK

Publications

  1. ncbi Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:185-92. 2006
  2. ncbi Ramelteon: profile of a new sleep-promoting medication
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:255-63. 2006
  3. ncbi Extended-release carbamazepine for acute bipolar mania: a review
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:283-9. 2006
  4. ncbi Extended-release zolpidem: efficacy and tolerability profile
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:721-7. 2006
  5. ncbi Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 43:249-58. 2007
  6. doi The year's new drugs & biologics, 2014: Part I
    A I Graul
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 51:37-87. 2015
  7. doi A report from the European Society of Cardiology Congress 2014 (August 30-September 3 - Barcelona, Spain)
    C Dulsat
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 50:653-7. 2014
  8. doi Parkinson's disease in the limelight
    A I Graul
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 50:641-5. 2014
  9. doi Pharmacovigilance Discussion Forum - The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015 - London, UK)
    S Lam
    Thomson Reuters, London, UK
    Drugs Today (Barc) 51:89-92. 2015
  10. doi Elosulfase alfa
    K Haddley
    Liverpool, UK
    Drugs Today (Barc) 50:475-83. 2014

Collaborators

Detail Information

Publications52

  1. ncbi Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:185-92. 2006
    ..The combination's possible mode of action, pharmacokinetics, drug interactions, clinical efficacy and safety and tolerability have been reviewed...
  2. ncbi Ramelteon: profile of a new sleep-promoting medication
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:255-63. 2006
    ....
  3. ncbi Extended-release carbamazepine for acute bipolar mania: a review
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:283-9. 2006
    ..It is effectively weight neutral and can provide an acceptable and efficacious treatment option for bipolar I mania...
  4. ncbi Extended-release zolpidem: efficacy and tolerability profile
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 42:721-7. 2006
    ..These findings have been echoed in a six-month study using an intermittent dosing paradigm with subjective endpoints...
  5. ncbi Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 43:249-58. 2007
    ..Body weight increased slightly, but the changes were acceptable in the context of the doses likely to be used clinically, and patients with higher initial body mass index gained less weight as has been reported for other antipsychotics...
  6. doi The year's new drugs & biologics, 2014: Part I
    A I Graul
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 51:37-87. 2015
    ..Another 19 products were approved for the first time during the year but not yet launched by close of this article; most are slated for launch in the first months of the new year. ..
  7. doi A report from the European Society of Cardiology Congress 2014 (August 30-September 3 - Barcelona, Spain)
    C Dulsat
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 50:653-7. 2014
    ..Apart from more than 4,500 interesting abstracts presented in posters and oral sessions, five new ESC Clinical Practice Guidelines were presented among the latest clinical trial results, updates and registries. ..
  8. doi Parkinson's disease in the limelight
    A I Graul
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 50:641-5. 2014
    ..This article reviews currently available therapies as well as biomarkers and novel diagnostics. ..
  9. doi Pharmacovigilance Discussion Forum - The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015 - London, UK)
    S Lam
    Thomson Reuters, London, UK
    Drugs Today (Barc) 51:89-92. 2015
    ....
  10. doi Elosulfase alfa
    K Haddley
    Liverpool, UK
    Drugs Today (Barc) 50:475-83. 2014
    ..Treatment increased clearance of glycosaminoglycans and induced gene expression consistent with improved chondrocyte function. Elosulfase alfa is approved for the treatment of MPS IVA in the U.S. and Europe. ..
  11. doi Vedolizumab for the treatment of inflammatory bowel disease
    K Haddley
    Freelance writer, Liverpool, UK
    Drugs Today (Barc) 50:309-19. 2014
    ..Regulatory applications are under review in the U.S. and E.U. for its use in the treatment of patients with UC and CD, with decisions expected in mid-2014...
  12. doi Spotlight on depression: a Pharma Matters report
    P D'Souza
    Thomson Reuters, London, UK
    Drugs Today (Barc) 50:251-67. 2014
    ..The lack of complete understanding of why depression occurs also makes this area a difficult one, although it opens the door for the development of drugs with novel mechanisms of action. ..
  13. doi Umeclidinium/vilanterol fixed-dose combination for COPD
    J Gras
    Barcelona, Spain
    Drugs Today (Barc) 50:231-8. 2014
    ..It has been filed for approval with the European Medicines Agency. ..
  14. doi The 32nd Annual J.P. Morgan Healthcare Conference (January 13-16, 2014 - San Francisco, California, USA): Auxilium Pharmaceuticals
    J Watt
    Thomson Reuters, London, UK
    Drugs Today (Barc) 50:269-71. 2014
    ..From a portfolio of 2 products at the beginning of 2013, Auxilium ended the year with 12. ..
  15. doi Turoctocog alfa for the treatment of hemophilia A
    K Haddley
    Liverpool, UK
    Drugs Today (Barc) 50:121-31. 2014
    ..The drug is FDA approved as a prophylactic agent and for on-demand treatment to control bleeding including during operative procedures. ..
  16. doi Cetilistat for the treatment of obesity
    J Gras
    Barcelona, Spain
    Drugs Today (Barc) 49:755-9. 2013
    ..Cetilistat showed mild to moderate adverse events, predominantly of gastrointestinal nature (steatorrhea), with an incidence lower than orlistat. It was recently approved in Japan for the treatment of obesity with complications. ..
  17. doi Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer
    K Haddley
    Liverpool, U K
    Drugs Today (Barc) 49:701-15. 2013
    ..Several phase II and III studies are under way investigating trastuzumab emtansine in combination with other regimens in patients with HER2-positive cancers. ..
  18. doi Bupivacaine liposome injectable suspension: a new approach to postsurgical pain
    R T Owen
    Freelance medical writer, Crewe, Cheshire, United Kingdom
    Drugs Today (Barc) 49:475-82. 2013
    ..Further larger studies are warranted, in particular using bupivacaine hydrochloride as the comparator. ..
  19. doi Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency
    K Haddley
    Drugs Today (Barc) 49:161-70. 2013
    ..The therapy is well tolerated in animals and humans and produces no serious treatment-related adverse effects...
  20. doi Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder
    R T Owen
    Crewe, Cheshire, UK
    Drugs Today (Barc) 49:195-201. 2013
    ..It produced a rapid calming effect without undue sedation. It was generally well tolerated, with dysgeusia being the most common adverse event...
  21. doi Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures
    R T Owen
    Freelance medical writer, Crewe, Cheshire, UK
    Drugs Today (Barc) 49:23-31. 2013
    ..Perampanel's efficacy and tolerability outcomes are broadly comparable with other agents licensed for adjunctive use in refractory partial onset seizures...
  22. doi The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome
    R T Owen
    Drugs Today (Barc) 48:697-703. 2012
    ..The data are discussed in terms of existing FDA-approved agents for Lennox-Gastaut syndrome and suggestions for further work...
  23. doi Tofacitinib for the treatment of moderate to severe rheumatoid arthritis
    J de Lartigue
    Camberley, Surrey, UK
    Drugs Today (Barc) 48:533-43. 2012
    ..It is currently under evaluation for approval for the treatment of adults with RA by several regulatory agencies around the world...
  24. doi Taliglucerase alfa for the treatment of Gaucher's disease
    K Haddley
    Drugs Today (Barc) 48:525-32. 2012
    ....
  25. doi Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole
    R T Owen
    Drugs Today (Barc) 48:469-78. 2012
    ..Although preclinical studies are discussed, the main focus of the review is on clinical outcomes...
  26. doi Tafamidis for transthyretin amyloidosis
    J de Lartigue
    Drugs Today (Barc) 48:331-7. 2012
    ..Tafamidis has been granted marketing authorization by the European Commission for the treatment of TTR-FAP and the U.S. Food and Drug Administration is currently reviewing this drug for the same indication...
  27. doi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:437-61. 2010
    ....
  28. doi Lurasidone: a new treatment option for schizophrenia
    R T Owen
    Crewe, Cheshire, UK
    Drugs Today (Barc) 47:807-16. 2011
    ..Raised prolactin levels in short-term studies were dose-dependent, greater in females and occurred overall in 3.7 and 0.7% of lurasidone and placebo recipients, respectively...
  29. doi Vilazodone: a new treatment option for major depressive disorder
    R T Owen
    Drugs Today (Barc) 47:531-7. 2011
    ..No important clinical changes in vital signs, laboratory values, ECG morphology and sexual function were observed or reported...
  30. doi Azilsartan medoxomil for the treatment of hypertension
    S Vasiliou
    Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 47:647-51. 2011
    ..In 2011, azilsartan medoxomil was approved in the U.S. for the treatment of hypertension...
  31. doi Corifollitropin alfa: a new option to treat female infertility
    Jane de Lartigue
    Surrey, UK
    Drugs Today (Barc) 47:583-90. 2011
    ..Therefore, corifollitropin alfa addresses the need for a simplified treatment approach to lessen the burden of multiple daily injections for in vitro fertilization...
  32. doi Eszopiclone: an update on its use in insomnia
    R T Owen
    Drugs Today (Barc) 47:263-75. 2011
    ..U.S.-based pharmacoeconomic data are included together with the design features of key regulatory studies submitted for regulatory approval in Japan...
  33. doi Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures
    Richard T Owen
    Drugs Today (Barc) 46:815-22. 2010
    ..The most common adverse events, comprising dizziness, somnolence, headache and fatigue, were dose-related and affected the central nervous system...
  34. doi Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 44:887-93. 2008
    ..Overall, the benefits of the CR formulation, among them the convenience of oncedaily dosing, were achieved without an increased adverse event burden versus the IR form...
  35. doi Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 45:261-7. 2009
    ..Doxepin was well tolerated; sedation/sleepiness and headache were the most common adverse events but these were mainly at placebo level or less. Further work is required to establish doxepin's low-dose effect on hypnotic activity...
  36. doi Novel zolpidem formulations
    Richard T Owen
    Medical Information Dept, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 45:395-400. 2009
    ..S. or are in the preregistration development phase. These comprise an extended-release form, two types of sublingual formulations and an oral spray. The pharmacokinetic and pharmacodynamic effects of these formulations are reviewed...
  37. doi Agomelatine: a novel pharmacological approach to treating depression
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 45:599-608. 2009
    ..Agomelatine is currently being investigated for other indications such as seasonal affective disorder, generalized anxiety disorder and bipolar depression...
  38. doi Rotigotine for restless legs syndrome
    Shelley Davies
    Medical Information Department, Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 45:663-8. 2009
    ..This system is designed to replace levels of dopamine in the body via once-daily application of the patch, in a bid to restore proper motor functioning. The rotigotine patch has been authorized for the treatment of RLS since August 2008...
  39. doi Dapoxetine: a novel treatment for premature ejaculation
    R T Owen
    Medical Information Department, Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 45:669-78. 2009
    ..Dapoxetine is generally well tolerated with a low incidence of discontinuations due to adverse events. There were no signals for treatment-emergent anxiety or SSRI discontinuation syndrome after abrupt withdrawal...
  40. doi Dabigatran etexilate in venous thromboembolism
    Elisa Ferrer
    Medical Information Department, Thomson Reuters, Barcelona, Spain
    Drugs Today (Barc) 45:715-24. 2009
    ....
  41. doi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:193-215. 2010
    ....
  42. doi Olanzapine: a review of rapid and long-acting parenteral formulations
    R T Owen
    Crewe, Cheshire, UK
    Drugs Today (Barc) 46:173-81. 2010
    ..The pivotal clinical trials of olanzapine rapid-acting intramuscular injection are reviewed in addition to post-hoc analyses, controlled and naturalistic studies since its launch...
  43. ncbi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:247-88. 2010
    ....
  44. doi Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia
    R T Owen
    Crewe, Cheshire, UK
    Drugs Today (Barc) 46:463-71. 2010
    ..It is available as prefilled syringes embracing a wide dose range (25, 50, 75, 100 and 150 mg eq.), and requires no refrigeration, reconstitution or oral antipsychotic supplementation...
  45. doi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:517-48. 2010
    ....
  46. ncbi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:599-620. 2010
    ....
  47. doi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:749-73. 2010
    ....
  48. doi Gateways to clinical trials
    A Tomillero
    Thomson Reuters, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 32:675-703. 2010
    ....
  49. doi Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 44:653-60. 2008
    ..Its safety and tolerability were typical of its class, and it was generally well tolerated. Further work will be required to establish its place in FMS therapy by comparing it directly with other agents...
  50. doi Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 43:857-63. 2007
    ..Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications...
  51. doi Lubiprostone--a novel treatment for irritable bowel syndrome with constipation
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 44:645-52. 2008
    ..Lubiprostone was well tolerated in the long-term, with nausea and diarrhea being the commonest adverse events. Further studies are ongoing in opioid-induced bowel dysfunction...
  52. doi Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy
    Richard T Owen
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 44:197-204. 2008
    ..There is no clear evidence of a withdrawal syndrome after abrupt cessation of therapeutic doses. Sodium oxybate appears to be an effective and well-tolerated treatment for all the key symptoms of the two forms of narcolepsy...